Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- VTYX
- Price
- 13.92
- Stock movement up
- +0.05 (0.36%)
- Company name
- Ventyx Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 998.76M
- Ent value
- 986.89M
- Price/Sales
- 689.75
- Price/Book
- 5.22
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 569.23%
- 3 year return (CAGR)
- -25.63%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-24
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VTYX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 689.75 |
| Price to Book | 5.22 |
| EV to Sales | 681.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.75M |
| EPS (TTM) | -1.50 |
| FCF per share (TTM) | -1.23 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.45M |
| Gross profit (TTM) | 45.00K |
| Operating income (TTM) | -116.72M |
| Net income (TTM) | -106.61M |
| EPS (TTM) | -1.50 |
| EPS (1y forward) | -1.63 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 3.11% |
| Operating margin (TTM) | -8060.91% |
| Profit margin (TTM) | -7362.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.97M |
| Net receivables | 500.00K |
| Total current assets | 201.09M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.99M |
| Total assets | 211.47M |
| Accounts payable | 993.00K |
| Short/Current long term debt | 10.02M |
| Total current liabilities | 11.26M |
| Total liabilities | 20.10M |
| Shareholder's equity | 191.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -87.75M |
| Capital expenditures (TTM) | 114.00K |
| Free cash flow (TTM) | -87.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -55.71% |
| Return on Assets | -50.41% |
| Return on Invested Capital | -55.37% |
| Cash Return on Invested Capital | -45.63% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 13.86 |
| Daily high | 13.94 |
| Daily low | 13.86 |
| Daily Volume | 1.61M |
| All-time high | 46.65 |
| 1y analyst estimate | 13.29 |
| Beta | 1.26 |
| EPS (TTM) | -1.50 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Mar 2026 |
Downside potential
Loading...
Downside potential data
| VTYX | S&P500 | |
| Current price drop from All-time high | -70.16% | -0.89% |
| Highest price drop | -98.21% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -60.76% | -10.84% |
| Avg time to new high | 51 days | 12 days |
| Max time to new high | 725 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
998.76M
Marketcap category
Small-cap
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Employees
83
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page